使用药物性锥体外系症状量表评估精神分裂症患者锥体外系症状的因素结构:来自2016年REAP AP-4研究的结果

IF 1.8 4区医学 Q3 CLINICAL NEUROLOGY

Human Psychopharmacology: Clinical and Experimental Pub Date : 2022-12-03 DOI:10.1002/hup.2861

Chika Kubota, Toshiya Inada, Shih-Ku Lin, Ajit Avasthi, Kok Yoon Chee, Andi Jayalangkara Tanra, Shu-Yu Yang, Lian-Yu Chen, Mian-Yoon Chong, Adarsh Tripathi, Roy Abraham Kallivayalil, Sandeep Grover, Seon-Cheol Park, Takahiro A. Kato, Yu-Tao Xiang, Kang Sim, Margarita M. Maramis, Isa Multazam Noor, Chay-Hoon Tan, Norman Sartorius, Naotaka Shinfuku

{"title":"使用药物性锥体外系症状量表评估精神分裂症患者锥体外系症状的因素结构:来自2016年REAP AP-4研究的结果","authors":"Chika Kubota, Toshiya Inada, Shih-Ku Lin, Ajit Avasthi, Kok Yoon Chee, Andi Jayalangkara Tanra, Shu-Yu Yang, Lian-Yu Chen, Mian-Yoon Chong, Adarsh Tripathi, Roy Abraham Kallivayalil, Sandeep Grover, Seon-Cheol Park, Takahiro A. Kato, Yu-Tao Xiang, Kang Sim, Margarita M. Maramis, Isa Multazam Noor, Chay-Hoon Tan, Norman Sartorius, Naotaka Shinfuku","doi":"10.1002/hup.2861","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Drug-induced extrapyramidal syndrome (EPS) remains a major problem in clinical psychiatry. This study aimed to examine the factor structure of drug-induced extrapyramidal symptoms observed in patients with schizophrenia and assessed using the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The participants were 1478 patients with a diagnosis of schizophrenia whose EPS was assessed using the DIEPSS in India, Indonesia, Japan, Malaysia, and Taiwan in the 2016 REAP AP-4 study. The records of the participants were randomly divided into two subgroups: the first for exploratory factor analysis of the eight DIEPSS items, and the second for confirmatory factor analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The factor analysis identified three factors: F1 (gait and bradykinesia), F2 (muscle rigidity and tremor), and F3 (sialorrhea, akathisia, dystonia, and dyskinesia).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The results suggest that the eight individual items of the DIEPSS could be composed of three different mechanisms: acute parkinsonism observed during action (F1), acute parkinsonism observed at rest (F2), and central dopaminergic mechanisms with pathophysiology other than acute parkinsonism (F3).</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"38 2","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2022-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The factor structure of extrapyramidal symptoms evaluated using the Drug-Induced Extrapyramidal Symptoms Scale in patients with schizophrenia: Results from the 2016 REAP AP-4 study\",\"authors\":\"Chika Kubota, Toshiya Inada, Shih-Ku Lin, Ajit Avasthi, Kok Yoon Chee, Andi Jayalangkara Tanra, Shu-Yu Yang, Lian-Yu Chen, Mian-Yoon Chong, Adarsh Tripathi, Roy Abraham Kallivayalil, Sandeep Grover, Seon-Cheol Park, Takahiro A. Kato, Yu-Tao Xiang, Kang Sim, Margarita M. Maramis, Isa Multazam Noor, Chay-Hoon Tan, Norman Sartorius, Naotaka Shinfuku\",\"doi\":\"10.1002/hup.2861\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>Drug-induced extrapyramidal syndrome (EPS) remains a major problem in clinical psychiatry. This study aimed to examine the factor structure of drug-induced extrapyramidal symptoms observed in patients with schizophrenia and assessed using the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>The participants were 1478 patients with a diagnosis of schizophrenia whose EPS was assessed using the DIEPSS in India, Indonesia, Japan, Malaysia, and Taiwan in the 2016 REAP AP-4 study. The records of the participants were randomly divided into two subgroups: the first for exploratory factor analysis of the eight DIEPSS items, and the second for confirmatory factor analysis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The factor analysis identified three factors: F1 (gait and bradykinesia), F2 (muscle rigidity and tremor), and F3 (sialorrhea, akathisia, dystonia, and dyskinesia).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The results suggest that the eight individual items of the DIEPSS could be composed of three different mechanisms: acute parkinsonism observed during action (F1), acute parkinsonism observed at rest (F2), and central dopaminergic mechanisms with pathophysiology other than acute parkinsonism (F3).</p>\\n </section>\\n </div>\",\"PeriodicalId\":13030,\"journal\":{\"name\":\"Human Psychopharmacology: Clinical and Experimental\",\"volume\":\"38 2\",\"pages\":\"\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2022-12-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Psychopharmacology: Clinical and Experimental\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/hup.2861\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2861","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

摘要

药物性锥体外系综合征(EPS)是临床精神病学的一个主要问题。本研究旨在探讨精神分裂症患者药物性锥体外系症状的因素结构，并采用药物性锥体外系症状量表(DIEPSS)进行评估。方法在2016年REAP AP-4研究中，参与者是印度、印度尼西亚、日本、马来西亚和台湾的1478名精神分裂症诊断患者，他们的EPS使用DIEPSS进行评估。将被试的记录随机分为两组:第一组用于DIEPSS八个项目的探索性因子分析，第二组用于验证性因子分析。结果因子分析确定了3个因素:F1(步态和运动迟缓)，F2(肌肉强直和震颤)，F3(唾液、静坐、肌张力障碍和运动障碍)。结论DIEPSS的8个单项可能由3种不同的机制组成:运动时观察急性帕金森病(F1)、静止时观察急性帕金森病(F2)和非急性帕金森病的中枢多巴胺能病理生理机制(F3)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The factor structure of extrapyramidal symptoms evaluated using the Drug-Induced Extrapyramidal Symptoms Scale in patients with schizophrenia: Results from the 2016 REAP AP-4 study

Introduction

Drug-induced extrapyramidal syndrome (EPS) remains a major problem in clinical psychiatry. This study aimed to examine the factor structure of drug-induced extrapyramidal symptoms observed in patients with schizophrenia and assessed using the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS).

Methods

The participants were 1478 patients with a diagnosis of schizophrenia whose EPS was assessed using the DIEPSS in India, Indonesia, Japan, Malaysia, and Taiwan in the 2016 REAP AP-4 study. The records of the participants were randomly divided into two subgroups: the first for exploratory factor analysis of the eight DIEPSS items, and the second for confirmatory factor analysis.

Results

The factor analysis identified three factors: F1 (gait and bradykinesia), F2 (muscle rigidity and tremor), and F3 (sialorrhea, akathisia, dystonia, and dyskinesia).

Conclusion

The results suggest that the eight individual items of the DIEPSS could be composed of three different mechanisms: acute parkinsonism observed during action (F1), acute parkinsonism observed at rest (F2), and central dopaminergic mechanisms with pathophysiology other than acute parkinsonism (F3).

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Human Psychopharmacology: Clinical and Experimental 医学-精神病学

CiteScore

4.10

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design